Discontinuation of secondary prophylaxis for penicilliosis marneffei in AIDS patients responding to highly active antiretroviral therapy [2]

CHIEN-CHING HUNGChen M.-Y.SZU-MIN HSIEHWANG-HUEI SHENGHsiao C.-F.SHAN-CHWEN CHANG2020-12-292020-12-2920020269-9370https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037040373&doi=10.1097%2f00002030-200203080-00022&partnerID=40&md5=edb3f75407f37bbfe683808cd727a235https://scholars.lib.ntu.edu.tw/handle/123456789/535445[SDGs]SDG3amphotericin B; antifungal agent; antiretrovirus agent; CD4 antigen; itraconazole; acquired immune deficiency syndrome; highly active antiretroviral therapy; human; Human immunodeficiency virus 1; Human immunodeficiency virus infection; letter; leukocyte count; major clinical study; mycosis; opportunistic infection; Penicillium marneffei; priority journal; treatment outcome; virus infection; AIDS-Related Opportunistic Infections; Antifungal Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Itraconazole; Mycoses; Penicillium; Withholding TreatmentDiscontinuation of secondary prophylaxis for penicilliosis marneffei in AIDS patients responding to highly active antiretroviral therapy [2]letter10.1097/00002030-200203080-0002211873014